| HDL as a target in the treatment of atherosclerotic cardiovascular disease. | |
| | |
MedLine Citation:
|
PMID: 15738977 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Lipid abnormalities are among the key risk factors for cardiovascular disease. Indeed, lipid-modifying drugs - in particular, the statins, which primarily lower plasma levels of low-density lipoprotein (LDL) cholesterol - considerably reduce the risk of cardiovascular events, leading to their widespread use. Nevertheless, it seems that there might be limits to the degree of benefit that can be achieved by lowering LDL-cholesterol levels alone, which has led to increased interest in targeting other lipid-related risk factors for cardiovascular disease, such as low levels of high-density lipoprotein (HDL) cholesterol. In this article, we first consider the mechanisms that underlie the protective effect of HDL cholesterol, and then discuss several strategies that have recently emerged to increase levels of HDL cholesterol to treat cardiovascular disease, including nuclear receptor modulation, inhibition of cholesteryl ester transfer protein and infusion of apolipoprotein/phospholipid complexes. |
| | |
Authors:
|
Patrick Linsel-Nitschke; Alan R Tall |
Related Documents
:
|
10877207 - Three-year study of estrogen alone versus combined with progestin in postmenopausal wom... 15303407 - Metabolic syndrome: soybean foods and serum lipids. 11487447 - New developments in the prevention of atherosclerosis in patients with low high-density... 6797787 - Lipoprotein patterns in women in santo domingo using a levonorgestrel/estradiol contrac... 18509197 - Composition of adipose tissue and marrow fat in humans by 1h nmr at 7 tesla. 17249687 - Application of gas chromatography-mass spectrometry metabolite profiling techniques to ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Nature reviews. Drug discovery Volume: 4 ISSN: 1474-1776 ISO Abbreviation: Nat Rev Drug Discov Publication Date: 2005 Mar |
Date Detail:
|
Created Date: 2005-03-01 Completed Date: 2005-04-01 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101124171 Medline TA: Nat Rev Drug Discov Country: England |
Other Details:
|
Languages: eng Pagination: 193-205 Citation Subset: IM |
Affiliation:
|
Division of Molecular Medicine, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10027, USA. pl2031@columbia.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Apolipoprotein A-I / administration & dosage, therapeutic use Arteriosclerosis / drug therapy*, etiology Cardiovascular Diseases / drug therapy*, etiology, prevention & control Carrier Proteins / antagonists & inhibitors* Cholesterol Ester Transfer Proteins Cholesterol, HDL / blood*, genetics, physiology Drug Delivery Systems Glycoproteins / antagonists & inhibitors* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Peroxisome Proliferator-Activated Receptors / agonists* Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoprotein A-I; 0/CETP protein, human; 0/Carrier Proteins; 0/Cholesterol Ester Transfer Proteins; 0/Cholesterol, HDL; 0/Glycoproteins; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Peroxisome Proliferator-Activated Receptors |
| Comments/Corrections | |
Erratum In:
|
Nat Rev Drug Discov. 2005 Aug;4(8):648 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Imaging of single light-responsive clock cells reveals fluctuating free-running periods.
Next Document: Therapeutic applications of polymeric artificial cells.